<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18517">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02151110</url>
  </required_header>
  <id_info>
    <org_study_id>D5100C00001</org_study_id>
    <nct_id>NCT02151110</nct_id>
  </id_info>
  <brief_title>A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 single IV dose study to evaluate safety and tolerability of MEDI4920
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of treatment emergent serious adverse events</measure>
    <time_frame>113 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability of MEDI4920 as measured by the incidence of treatment-emergent serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>113 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measured by incidence of treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MEDI4920 plasma concentrations</measure>
    <time_frame>113 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MEDI4920 plasma concentrations will be summarized by dose and time point. Non-compartmental PK data analysis will be performed for MEDI4920-treated subjects to estimate the AUC, Cmax, terminal half-life (t1/2), systemic clearance (CL) and V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of positive ADA against MEDI4920</measure>
    <time_frame>113 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Plasma samples will be collected for the assessment of ADA against MEDI4920. The ADA results will be summarized by the number and percentage of subjects positive for ADA at baseline and positive at any post-baseline time point. For those with a positive post-baseline assessment the percentage who was persistent positive and transient positive will also be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adequate inhibition of T-cell dependent antibody response</measure>
    <time_frame>113 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Achieving greater than or equal to a predetermined reduction of the anti-KLH IgG response</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medi4920</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4920</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4920</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4920</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4920</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4920</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4920</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4920</intervention_name>
    <description>CD40L antagonist</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% saline for injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy as determined by a responsible study physician based on medical evaluation

          -  Body weight 40 to 100 kg

          -  Body mass index 19.0 to 30.0 kg/m2

        Exclusion Criteria:

          -  History of allergy or sensitivity to Shellfish or protein based antigens

          -  previous immunization with KLH

          -  previous splenectomy

          -  History of diagnosed or suspected thromboembolic event or coagulation disorder
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medimmune Contact</last_name>
    <email>ClinicalTrialEnquiries@Medimmune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>May 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Male</keyword>
  <keyword>Healthy Female of non child bearing potential</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
